SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:liu-203252"
 

Search: onr:"swepub:oai:DiVA.org:liu-203252" > Obesity is a risk f...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Dubovyk, ViolettaUniv Gothenburg, Sweden (author)

Obesity is a risk factor for poor response to treatment in early rheumatoid arthritis: a NORD-STAR study

  • Article/chapterEnglish2024

Publisher, publication year, extent ...

  • BMJ PUBLISHING GROUP,2024
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:liu-203252
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-203252URI
  • https://doi.org/10.1136/rmdopen-2024-004227DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Funding Agencies|Swedish Research Council [2021-01442]; Swedish Society for Medical Research [S20-0109]; Knut and Alice Wallenberg Foundation; Wallenberg Centre for Molecular and Translational Medicine at the University of Gothenburg; Swedish Federal Government under LUA/ALF agreement; ALF [ALFGBG-965478, ALFGBG-978776]; Konung Gustav V Foundation; Swedish Association Against Rheumatism [R-969009, R-982136]; National Institute for Health Research Clinical Lectureship; Versus Arthritis [21173, 21754, 21755]
  • Objective This report from the NORD-STAR (Nordic Rheumatic Diseases Strategy Trials and Registries) trial aimed to determine if obesity is associated with response to conventional and biological antirheumatic treatment in early rheumatoid arthritis (RA). Methods This report included 793 participants with untreated early RA from the randomised, longitudinal NORD-STAR trial, all of whom had their body mass index (BMI) assessed at baseline. Obesity was defined as BMI >= 30 kg/m(2). All participants were randomised 1:1:1:1 to one of four treatment arms: active conventional treatment, certolizumab-pegol, abatacept and tocilizumab. Clinical and laboratory measurements were performed at baseline and at 8, 12, 24 and 48-week follow-up. The primary endpoint for this report was response to treatment based on Clinical Disease Activity Index (CDAI) and Simple Disease Activity Index (SDAI) remission and Disease Activity Score with 28 joints using C-reactive protein (DAS28-CRP) <2.6 stratified by BMI. Results Out of 793 people included in the present report, 161 (20%) had obesity at baseline. During follow-up, participants with baseline obesity had higher disease activity compared with those with lower BMI, despite having similar disease activity at baseline. In survival analyses, obesity was associated with a lower likelihood of achieving response to treatment during follow-up for up to 48 weeks (CDAI remission, HR 0.84, 95% CI 0.67 to 1.05; SDAI, HR 0.77, 95% CI 0.62 to 0.97; DAS28-CRP <2.6, HR 0.78, 95% CI 0.64 to 0.95). The effect of obesity on response to treatment was not influenced by the treatment arms. Conclusion In people with untreated early RA followed up for up to 48 weeks, obesity was associated with a lower likelihood of good treatment response, irrespective of the type of randomised treatment received.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Vasileiadis, Georgios K.Univ Gothenburg, Sweden (author)
  • Fatima, TahzeebUniv Gothenburg, Sweden (author)
  • Zhang, YuanUniv Gothenburg, Sweden (author)
  • Kapetanovic, Meliha CrnkicSkane Univ Hosp Lund, Sweden (author)
  • Kastbom, AlfLinköpings universitet,Avdelningen för inflammation och infektion,Medicinska fakulteten,Region Östergötland, Reumatologiska kliniken i Östergötland(Swepub:liu)alfka05 (author)
  • Rizk, MiladVastmanlands Hosp, Sweden (author)
  • Soederbergh, AnnikaOrebro Univ Hosp, Sweden (author)
  • Zhao, Sizheng StevenUniv Manchester, England (author)
  • van Vollenhoven, Ronald F.Amsterdam Rheumatol & Immunol Ctr, Netherlands; Karolinska Inst, Sweden (author)
  • Hetland, Merete LundRigshosp Glostrup, Denmark; Univ Copenhagen, Denmark (author)
  • Haavardsholm, Espen A.Diakonhjemmet Hosp, Norway; Univ Oslo, Norway (author)
  • Nordstrom, DanUniv Helsinki, Finland (author)
  • Nurmohamed, Michael T.Amsterdam Rheumatol & Immunol Ctr, Netherlands; Amsterdam Rheumatol & Immunol Ctr, Netherlands (author)
  • Gudbjornsson, BjornUniv Iceland, Iceland; Landspitali Univ Hosp, Iceland (author)
  • Lampa, JonKarolinska Inst, Sweden (author)
  • Ostergaard, MikkelRigshosp Glostrup, Denmark; Univ Copenhagen, Denmark (author)
  • Heiberg, Marte SchrumpfDiakonhjemmet Hosp, Norway (author)
  • Sokka-Isler, TuulikkiUniv Eastern Finland, Finland (author)
  • Grondal, GerdurUniv Iceland, Iceland; Landspitali Univ Hosp, Iceland (author)
  • Lend, KristinaAmsterdam Rheumatol & Immunol Ctr, Netherlands; Karolinska Inst, Sweden (author)
  • Horslev-Petersen, KimUniv Hosp Southern Denmark, Denmark; Univ Southern Denmark, Denmark (author)
  • Uhlig, TillDiakonhjemmet Hosp, Norway; Univ Oslo, Norway (author)
  • Rudin, AnnaUniv Gothenburg, Sweden (author)
  • Maglio, CristinaUniv Gothenburg, Sweden (author)
  • Univ Gothenburg, SwedenSkane Univ Hosp Lund, Sweden (creator_code:org_t)

Related titles

  • In:RMD Open: BMJ PUBLISHING GROUP10:22056-5933

Internet link

Find in a library

  • RMD Open (Search for host publication in LIBRIS)

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view